Florida based company REMware has signed an agreement with virtual medical practice, Side Health to provide patients with a home testing solution for sleep apnoea.
Dream Clear from REMware is a remote sleep apnoea testing device designed to be used by the patient at home and supplies the recorded data to your doctor or healthcare provider through its home sleep test (HST) app.
Side Health patients can request the device online and have it delivered to their address and within 30 minutes of waking up the device and HST app track their sleep data which is then uploaded to the cloud. The data is summarised by measuring eye movement, oxygen levels, heart rate, breathing, snoring, EEG, and body position.
Side Health uses several devices to test and monitor in real time for hypertension, diabetes, heart disease, COPD, allergies, weight management and sleep apnoea to reduce face to face assessments.
REMware claims to have a 99% success rate working with its partners for home sleep testing which they attribute to its platform that uses automated texts and emails paired with an in-house support service.
“The proprietary technology and process yields the same thorough assessment of Obstructive Sleep Apnea (OSA) and Central Sleep Apnea when compared to in-lab polysomnography tests, giving providers the opportunity to treat, educate and provide follow-up care virtually,” said REMware CEO Arun Ramabadran.
Over 85% of the worldwide population are reported to go undiagnosed with OSA and more than 25 million suffer from it in the US. According to Side Health CEO Dr. Kanwar Kelley, data from 2023 suggests that 26% of the US adult population between the ages of 30 to 70 have the condition. If left untreated OSA can lead to heart conditions, strokes, high blood pressure and more.
GlobalData expects the device market to grow rapidly, mainly due to an increasing global population and growing awareness of apps and testing devices in the region of North America.
Risk factors such as obesity, aging, menopause, craniofacial abnormalities, upper airway anatomy, smoking, alcohol, and genetic predisposition, contribute to more OSA cases and high obesity rate makes the US market more lucrative than other regions.
Recently London based company Acurable announced its plans to target the US market with AcuPebble following two years of testing its device through the NHS.